Joining the podcast today is Mark Muzzin, Managing Director of Nexsen Ltd (ASX: NXN). Mark speaks about how Nexsen is building next-generation rapid diagnostics, the company’s strategic direction, the development of its sensor platform, and the clinical and commercial pathways ahead.

1. Introduction to Company

“Mark, to begin, can you give us a clear introduction to Nexsen — what the company does, the problem it is solving in healthcare, and how its diagnostic platform stands apart?”

2. Strategy

“What is Nexsen’s overarching strategy for advancing its sensor technology from development to clinical adoption and ultimately commercial rollout?”

3. Flagship Programs / Lead Assays

“Can you walk us through Nexsen’s lead diagnostic programs — including the rapid Group ...